Controlled dangerous substances; adding chemicals to Schedule I; effective date.
Summary
HB1311 amends Oklahoma’s Uniform Controlled Dangerous Substances Act to expand Schedule I by adding a large number of specific chemicals and chemical families. The bill lists numerous synthetic opioids, fentanyl-related compounds, opium derivatives, hallucinogens, stimulants, depressants, and synthetic cannabinoids, including many emerging designer drugs and analogs. It also expressly covers certain industrial chemicals when packaged or marketed for human consumption, while carving out specified legitimate industrial uses and allowing the Oklahoma State Bureau of Narcotics and Dangerous Drugs Control to exempt other legitimate industrial products after notice and hearing.
The bill also includes a federal-conformity provision for prescription drugs approved by the FDA that are later designated, rescheduled, or deleted as controlled substances by the DEA. In those cases, the drug would be excluded from Schedule I and treated in accordance with federal law unless the Oklahoma State Board of Pharmacy acts under existing state procedures. The act is set to take effect November 1, 2025.
Impact
HB1311 would broaden Oklahoma’s Schedule I controlled substances list and give state law enforcement and regulators additional authority to treat newly identified synthetic drugs, fentanyl analogs, and synthetic cannabinoids as prohibited controlled dangerous substances. It would also preserve exemptions for certain industrial products and uses of chemicals such as GBL, GHV, GVL, and 1,4-butanediol, and it would align state treatment of certain FDA-approved prescription drugs with federal DEA scheduling actions unless the State Board of Pharmacy intervenes under current law.
Sentiment
No committee transcripts or recorded votes were provided, so there is no direct evidence of debate or formal support/opposition in the available materials. Based on the bill text alone, the measure appears to be a public-safety and drug-control update aimed at keeping pace with evolving synthetic substances and fentanyl-related compounds. The overall framing is regulatory and enforcement-oriented rather than controversial in the text itself.
Contention
The main potential points of contention are the breadth and specificity of the Schedule I additions, especially the inclusion of many synthetic cannabinoids, fentanyl analogs, and other designer drugs that may be used in research or have closely related chemical structures. Another likely issue is the treatment of industrial chemicals that can have legitimate non-drug uses, since the bill relies on exemptions and administrative review by the Bureau of Narcotics and Dangerous Drugs Control. The federal-conformity provision could also raise questions about how quickly state law should follow DEA scheduling decisions and the role of the State Board of Pharmacy in preserving or changing state classification.